Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of a Maintenance Therapy With Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Chemosensitive Relapsed Multiple Myeloma

NCT01421927 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT01421927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01421927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of a Maintenance Therapy With Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Chemosensitive Relapsed Multiple Myeloma
Lead sponsor
University Hospital, Bordeaux
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2011
Completion date
October 31, 2014
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma